# OnCo record golidocitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/golidocitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "golidocitinib" ;
  schema:name "Golidocitinib"@en ;
  schema:description "Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/golidocitinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=DZD4205> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral selective JAK1 inhibitor" ;
  onco:approval "CN 2024: Relapsed or refractory peripheral T-cell lymphoma" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/jak1/> ;
  onco:companies <https://onco.cc/companies/dizal/> ;
  onco:trials <https://onco.cc/trials/nct07234162/>, <https://onco.cc/trials/nct07496229/> .